Pallas Capital Advisors LLC Has $1.09 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Pallas Capital Advisors LLC raised its position in Natera, Inc. (NASDAQ:NTRA) by 6.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,865 shares of the medical research company’s stock after acquiring an additional 396 shares during the period. Pallas Capital Advisors LLC’s holdings in Natera were worth $1,087,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Wellington Management Group LLP raised its stake in shares of Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after purchasing an additional 1,883,481 shares in the last quarter. Farallon Capital Management LLC raised its stake in shares of Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after buying an additional 532,874 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Natera by 257.6% during the 2nd quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock worth $70,553,000 after acquiring an additional 469,327 shares during the period. PointState Capital LP boosted its position in shares of Natera by 112.0% during the 3rd quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock valued at $99,343,000 after acquiring an additional 413,468 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in Natera by 53.6% in the second quarter. Marshall Wace LLP now owns 958,383 shares of the medical research company’s stock valued at $103,783,000 after acquiring an additional 334,630 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Stock Down 3.3 %

NASDAQ NTRA opened at $169.30 on Tuesday. The stock has a market capitalization of $22.35 billion, a P/E ratio of -96.19 and a beta of 1.65. Natera, Inc. has a 52 week low of $59.80 and a 52 week high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a fifty day moving average of $160.14 and a 200-day moving average of $132.44.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period last year, the company earned ($0.95) earnings per share. The company’s revenue was up 63.9% on a year-over-year basis. On average, equities research analysts forecast that Natera, Inc. will post -1.61 EPS for the current year.

Insider Activity at Natera

In related news, CFO Michael Burkes Brophy sold 608 shares of Natera stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $120.76, for a total transaction of $73,422.08. Following the transaction, the chief financial officer now owns 74,014 shares of the company’s stock, valued at $8,937,930.64. This trade represents a 0.81 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 1,709 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $120.76, for a total transaction of $206,378.84. Following the completion of the sale, the chief executive officer now directly owns 194,615 shares of the company’s stock, valued at $23,501,707.40. The trade was a 0.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 123,409 shares of company stock worth $20,045,631 over the last ninety days. Company insiders own 7.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Piper Sandler boosted their price target on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, November 18th. The Goldman Sachs Group increased their price objective on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Finally, Morgan Stanley increased their target price on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $158.00.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.